Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis

Overview

Journal J Pers Med

Date 2024 Jun 27

PMID 38929778

Authors

Silviu Constantin Latcu

Razvan Bardan

Alin Adrian Cumpanas

Vlad Barbos

Flavia Baderca

Pusa Nela Gaje

Raluca Amalia Ceausu

Serban Comsa

Cristina-Stefania Dumitru

Raluca Dumache

Talida Georgiana Cut

Voichita Elena Lazureanu

Ligia Petrica

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) remains incurable in advanced stages. Biomarkers have proven to be quite useful in cancer therapeutics. Herein, we provide a comparative/integrative statistical analysis of seminal immunohistochemistry (IHC) findings for Wilms' Tumor 1 antigen (WT1) and thymine dimers (TDs), emerging as atypical, yet promising, potential biomarkers for RCCs. We assessed WT1/TD reactivity in adult RCC tumor cells, tumor microenvironment (TME), and tumor-adjacent healthy renal tissue (HRT). WT1 positivity was scarce and strictly nuclear in tumor cells, whereas TD-reactive tumor tissues were prevalent. We report statistically significant positive correlations between the density of reactive RCC cellularity and the intensity of nuclear staining for both biomarkers (WT1 - rho = 0.341, -value = 0.036; TDs - rho = 0.379, -value = 0.002). RCC stromal TME TD-positivity was much more frequent than WT1 reactivity, apparently proportional to that of the proper RCC cellularity and facilitated by extensive RCC inflammatory infiltration. TDs exhibited nuclear reactivity for most TME cell lines, while RCC TME WT1 expression was rare and inconsistent. In HRTs, TDs were entirely restricted to renal tubular cells, the likely cellular progenitor of most conventional RCC subtypes. In lieu of proper validation, these early findings have significant implications regarding the origins/biology of RCCs and may inform RCC therapeutics, both accounting for the high frequency of immunotherapy-permissive frameshift indels in RCCs, but also hinting at novel predictive clinical tools for WT1-targeted immunotherapy. Overall, the current study represents a meek yet hopefully significant step towards understanding the molecular biology and potential therapeutic targets of RCCs.

Citing Articles

Antioxidant Defenses, Oxidative Stress Responses, and Apoptosis Modulation in Spontaneous Abortion: An Immunohistochemistry Analysis of First-Trimester Chorionic Villi.

Vornic I, Nesiu A, Ardelean A, Todut O, Pasare V, Onel C Life (Basel). 2024; 14(9).

PMID: 39337859 PMC: 11432807. DOI: 10.3390/life14091074.

References

Zhou M, Roma A, Magi-Galluzzi C . The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005; 25(2):247-57. DOI: 10.1016/j.cll.2005.01.004. View

Leong Y, DAmbrosio S . DNA repair following ultraviolet and N-ethyl-N-nitrosourea treatment of cells cultured from human fetal brain, intestine, kidney, liver, and skin. Cancer Res. 1983; 43(12 Pt 1):5846-50. View

Gessler M, Poustka A, Cavenee W, Neve R, Orkin S, BRUNS G . Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990; 343(6260):774-8. DOI: 10.1038/343774a0. View

Chau Y, Hastie N . The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet. 2012; 28(10):515-24. DOI: 10.1016/j.tig.2012.04.004. View

Hansen U, Ramskov S, Bjerregaard A, Borch A, Andersen R, Draghi A . Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. Front Immunol. 2020; 11:373. PMC: 7080703. DOI: 10.3389/fimmu.2020.00373. View

Hastie N . Wilms' tumour 1 (WT1) in development, homeostasis and disease. Development. 2017; 144(16):2862-2872. DOI: 10.1242/dev.153163. View

Clingen P, Arlett C, Cole J, Waugh A, Lowe J, HARCOURT S . Correlation of UVC and UVB cytotoxicity with the induction of specific photoproducts in T-lymphocytes and fibroblasts from normal human donors. Photochem Photobiol. 1995; 61(2):163-70. DOI: 10.1111/j.1751-1097.1995.tb03955.x. View

Novacescu D, Latcu S, Bardan R, Daminescu L, Cumpanas A . Contemporary Biomarkers for Renal Transplantation: A Narrative Overview. J Pers Med. 2023; 13(8). PMC: 10456039. DOI: 10.3390/jpm13081216. View

Choueiri T, Pal S, McDermott D, Morrissey S, Ferguson K, Holland J . A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25(8):1603-8. PMC: 6279111. DOI: 10.1093/annonc/mdu184. View

10.

Jhappan C, Noonan F, Merlino G . Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003; 22(20):3099-112. DOI: 10.1038/sj.onc.1206450. View

11.

Kane C, Mallin K, Ritchey J, Cooperberg M, Carroll P . Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008; 113(1):78-83. DOI: 10.1002/cncr.23518. View

12.

Kreidberg J, Sariola H, LORING J, Maeda M, Pelletier J, Housman D . WT-1 is required for early kidney development. Cell. 1993; 74(4):679-91. DOI: 10.1016/0092-8674(93)90515-r. View

13.

Chae Y, Viveiros P, Lopes G, Sukhadia B, Sheikh M, Saravia D . Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol. 2019; 14(10):1807-1817. DOI: 10.1016/j.jtho.2019.06.016. View

14.

Klatte T, Seligson D, Riggs S, Leppert J, Berkman M, Kleid M . Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(24):7388-93. DOI: 10.1158/1078-0432.CCR-07-0411. View

15.

Gao L, Bellantuono I, Elsasser A, Marley S, Gordon M, Goldman J . Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000; 95(7):2198-203. View

16.

Hohenstein P, Hastie N . The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006; 15 Spec No 2:R196-201. DOI: 10.1093/hmg/ddl196. View

17.

Roos W, Kaina B . DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2012; 332(2):237-48. DOI: 10.1016/j.canlet.2012.01.007. View

18.

van Kranen H, de Gruijl F, De Vries A, Sontag Y, Wester P, Senden H . Frequent p53 alterations but low incidence of ras mutations in UV-B-induced skin tumors of hairless mice. Carcinogenesis. 1995; 16(5):1141-7. DOI: 10.1093/carcin/16.5.1141. View

19.

Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M . Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. iScience. 2020; 23(4):100998. PMC: 7188741. DOI: 10.1016/j.isci.2020.100998. View

20.

You Y, Szabo P, Pfeifer G . Cyclobutane pyrimidine dimers form preferentially at the major p53 mutational hotspot in UVB-induced mouse skin tumors. Carcinogenesis. 2000; 21(11):2113-7. DOI: 10.1093/carcin/21.11.2113. View